Skip to main content

Table 3 Specific gallbladder findings (per Independent Ultrasound Review)

From: The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

  Arm A Arm B Arm C
  Motesanib 125 mg QD Motesanib 75 mg BID Motesanib 75 mg BID
   2 wk on/1 wk off 5 d on/2 d off
Patient incidence, n (%) Baseline Post baseline* Post treatment Baseline Post baseline* Post treatment Baseline Post baseline* Post treatment
  (n = 23) (n = 23) (n = 16) (n = 11) (n = 11) (n = 9) (n = 11) (n = 11) (n = 8)
Gallstones 3 (13) 4 (17) 3 (19) 3 (27) 2 (18) 2 (22) 0 (0) 0 (0) 0 (0)
Sludge 0 (0) 9 (39) 4 (25) 0 (0) 4 (36) 4 (44) 0 (0) 3 (27) 0 (0)
Pericholecystic fluid 0 (0) 1 (4) 0 (0) 1 (9) 1 (9) 0 (0) 0 (0) 0 (0) 0 (0)
Common duct dilation 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
  1. *Data within the table indicate number of patients with at least one incidence of the specific gallbladder findings listed at any point during postbaseline treatment.
  2. Data within the table indicate number of patients who had the specific gallbladder findings listed at their last available off-treatment assessment.
\